UK clears Glaxo’s $700,000 ‘bubble boy disease’ treatment
Bloomberg The UK’s thrifty health authority has cleared its most expensive medicine ever—a $700,000 GlaxoSmithKline Plc treatment for an illness known as “bubble-boy disease.†But the overall cost to the country’s medical system won’t be as eye-popping as the price suggests. Glaxo, Britain’s biggest drugmaker, said it has treated four patients with Strimvelis since it was approved by the European ...
Read More »
The Gulf Time Newspaper One of the finest business newspapers in the UAE brought to you by our professional writers and editors.